ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study…
Media, Policymaker, and Investor Participation Grows as Interest Surges in AI, Robotics, and Marketing & Advertising ARLINGTON, Va., March 31,…
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…